These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34350059)

  • 41. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
    Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
    Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors.
    Mortezaee K; Majidpoor J
    Biomed Pharmacother; 2023 Jun; 162():114621. PubMed ID: 37004328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
    Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
    Front Immunol; 2021; 12():654080. PubMed ID: 34040604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-throughput cytotoxicity and antigen-binding assay for screening small bispecific antibodies without purification.
    Sugiyama A; Umetsu M; Nakazawa H; Niide T; Asano R; Hattori T; Kumagai I
    J Biosci Bioeng; 2018 Aug; 126(2):153-161. PubMed ID: 29548844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [An anti-P-gp/anti-CD3 bispecific antibody cytotoxic to human multidrug resistant KB cells].
    Gao YD; Xiong DS; Yang M; Xu YF; Shao XF; Peng H; Fan DM; Yang CZ
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):653-6. PubMed ID: 16438884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody.
    Gao Y; Xiong D; Yang M; Liu H; Peng H; Shao X; Xu Y; Xu C; Fan D; Qin L; Yang C; Zhu Z
    Leukemia; 2004 Mar; 18(3):513-20. PubMed ID: 14981526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment.
    Kuang Z; Pu P; Wu M; Wu Z; Wang L; Li Y; Zhang S; Jing H; Wu W; Chen B; Liu J
    Mol Cancer Ther; 2020 Dec; 19(12):2564-2574. PubMed ID: 32999045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis.
    Hassanzadeh Eskafi A; Oghalaei A; Mahboudi F; Ghaderi H; Behdani M; Shoari A; Kazemi-Lomedasht F
    Immunopharmacol Immunotoxicol; 2023 Apr; 45(2):197-202. PubMed ID: 36193665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microenvironment-responsive anti-PD-L1 × CD3 bispecific T-cell engager for solid tumor immunotherapy.
    Liu D; Bao L; Zhu H; Yue Y; Tian J; Gao X; Yin J
    J Control Release; 2023 Feb; 354():606-614. PubMed ID: 36669532
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
    Liang Z; Li Y; Tian Y; Zhang H; Cai W; Chen A; Chen L; Bao Y; Xiang B; Kan H; Li Y
    Cancer Lett; 2019 Apr; 447():164-173. PubMed ID: 30677447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
    Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
    J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.
    Mølgaard K; Compte M; Nuñez-Prado N; Harwood SL; Sanz L; Alvarez-Vallina L
    Gene Ther; 2017 Apr; 24(4):208-214. PubMed ID: 28075428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.
    Yoon A; Lee S; Lee S; Lim S; Park YY; Song E; Kim DS; Kim K; Lim Y
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32143496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.